<DOC>
	<DOCNO>NCT00064584</DOCNO>
	<brief_summary>This first study drug CT53518 give human . The purpose study determine high dose CT53518 safely give patient Acute Myelogenous Leukemia ( AML ) identify side effect associate take drug . The study evaluate CT53518 absorbed , break , eliminate body . Additionally , study evaluate effect drug specific type cell bone marrow blood , know blast .</brief_summary>
	<brief_title>Safety Tolerance Study Oral Doses CT53518 Treat Patients With Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>This Phase 1 , open label , dose escalate study five clinical site determine dose limit toxicity ( DLT ) , maximum tolerate dose ( MTD ) , pharmacokinetics , effect peripheral bone marrow blast count oral 28-day course CT53518 patient Acute Myelogenous Leukemia ( AML ) myelodysplastic syndrome . This study confirm tolerability ass effect peripheral bone marrow blast count oral 28-day course CT53518 near maximum tolerate dose patient AML display specify mutation FLT-3 gene , internal tandem duplication ( ITD ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion eligible participate study . Men woman 18 year age one follow condition : AML relapse within 12 month completion consolidation therapy receive gemtuzumabozogamicin ; AML relapse 12 month completion consolidation therapy , opinion investigator , risk alternative therapy outweigh possible benefit ; newly diagnose AML refractory conventional remissioninduction chemotherapy ( `` refractory '' define &gt; 10 % blast blood and/or bone marrow upon recovery two cycle standard cytarabinebased induction chemotherapy ) ; newly diagnose , previously treat AML , great 60 year age longer candidate conventional remissioninduction chemotherapy gemtuzumabozogamicin No reproductive potential ( surgically , post menopausal , use two method contraception ) Demonstrated FLT3 gene , internal tandem duplication mutation ECOG performance status 0 2 Has receive cytoreductive drug therapy least 4 week , receive hydroxyurea within 24 hour prior first dose study drug Has receive bone marrow transplant peripheral blood stem cell transplant within last two month Able read give write informed consent sign consent form approve Investigator 's Institutional Review Board ( IRB ) Patients meet follow criterion eligible participate study : Participated investigational drug study last 30 day Serum Creatinine &gt; 2 mg/dL Evidence clinically significant liver disease history , physical examination and/or laboratory data ( e.g . transaminase exceed 3 x ULN and/or total bilirubin &gt; 2 mg/dL Known use illicit drug within last 30 day Has uncontrolled active infection Pregnant nursing mother Candidate conventional chemotherapy ( except hydroxyurea ) , include growth factor hormonal therapy cancer Any concomitant disease condition could interfere treatment might interfere conduct study , would , opinion Investigator and/or Sponsor , increase risk patient 's participation study . This include limited alcoholism , drug dependency abuse , psychiatric disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>